Last reviewed · How we verify

NCT06567652

Safety and Efficacy of Persistent Atrial Fibrillation Ablation With a Cryoballoon Technology

Completed Last updated 27 August 2024
What this trial tests

trial testing catheter ablation in Atrial Fibrillation in 80 participants. Completed in 1 September 2022.

Timeline
1 January 2021
Primary endpoint
31 August 2022
1 September 2022

Quick facts

Lead sponsorUniversitair Ziekenhuis Brussel
StatusCompleted
Study typeOBSERVATIONAL
Enrollment80
Start date1 January 2021
Primary completion31 August 2022
Estimated completion1 September 2022
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitair Ziekenhuis Brussel — full company profile →

Who can join

Adults 18 to 90, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this retrospective observational study is to learn about the safety and efficacy of cryoballoon catheter ablation in 80 patients with persistent atrial fibrillation using the PolarX (Boston scientific) cryoablation technology. The main question it aims to answer is if it is safe and effective.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of catheter ablation

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Universitair Ziekenhuis Brussel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing